Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
US11565005B2 · kind B2 · utility
0Cited by
2References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 5, 2018 |
| Grant date | Jan 31, 2023 |
| Priority date | — |
| Expiry date | Jul 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.